ECSP056014A - MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA - Google Patents

MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA

Info

Publication number
ECSP056014A
ECSP056014A EC2005006014A ECSP056014A ECSP056014A EC SP056014 A ECSP056014 A EC SP056014A EC 2005006014 A EC2005006014 A EC 2005006014A EC SP056014 A ECSP056014 A EC SP056014A EC SP056014 A ECSP056014 A EC SP056014A
Authority
EC
Ecuador
Prior art keywords
1beta
specificity
il
human
antibody molecules
Prior art date
Application number
EC2005006014A
Other languages
English (en)
Inventor
Alastair David Griffiths Lawson
Andrew George Popplewell
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB0303337.0A priority Critical patent/GB0303337D0/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of ECSP056014A publication Critical patent/ECSP056014A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Abstract

La invención se refiere a una molécula de anticuerpo que tiene especificidad para determinantes antigénicos de IL-1ß, usos terapéuticos de la molécula de anticuerpo y métodos para producir dicha molécula de anticuerpo.
EC2005006014A 2003-02-13 2005-09-13 MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA ECSP056014A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB0303337.0A GB0303337D0 (en) 2003-02-13 2003-02-13 Biological products

Publications (1)

Publication Number Publication Date
ECSP056014A true ECSP056014A (es) 2006-01-27

Family

ID=9952969

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006014A ECSP056014A (es) 2003-02-13 2005-09-13 MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA

Country Status (26)

Country Link
US (2) US7608694B2 (es)
EP (2) EP2287193A1 (es)
JP (2) JP4668896B2 (es)
KR (1) KR20050099509A (es)
CN (1) CN1745103A (es)
AR (1) AR043159A1 (es)
AT (1) AT525397T (es)
AU (1) AU2004210776B2 (es)
BR (1) BRPI0407233A (es)
CA (1) CA2515474C (es)
CL (1) CL2004000259A1 (es)
CY (1) CY1112507T1 (es)
DK (1) DK1597282T3 (es)
EA (1) EA200501286A1 (es)
EC (1) ECSP056014A (es)
ES (1) ES2373953T3 (es)
GB (1) GB0303337D0 (es)
IS (1) IS8013A (es)
MX (1) MXPA05007392A (es)
NO (1) NO20054223L (es)
PE (1) PE20040947A1 (es)
PL (1) PL378412A1 (es)
PT (1) PT1597282E (es)
SI (1) SI1597282T1 (es)
TW (1) TW200505942A (es)
WO (1) WO2004072116A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
EP2361933A3 (en) * 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
AT446972T (de) 2005-06-21 2009-11-15 Xoma Technology Ltd Il-1 bindende antikörper und fragmente davon
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
JP5183484B2 (ja) 2005-12-09 2013-04-17 ユセベ ファルマ ソシエテ アノニム ヒトil−6に対して特異性を有する抗体分子
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
MX2009006709A (es) 2006-12-20 2009-07-02 Xoma Technology Ltd Tratamiento de enfermedades relacionadas con il-1beta.
KR101605908B1 (ko) 2007-03-22 2016-03-23 바이오젠 엠에이 인코포레이티드 Cd154에 특이적으로 결합하는, 항체, 항체 유도체 및 항체 단편을 포함하는 결합 단백질, 및 그의 용도
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
CA2710252C (en) 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
EA201001691A1 (ru) * 2008-04-28 2011-10-31 Калобайос Фармасьютикалз, Инк. Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
WO2010028273A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function
JP5782385B2 (ja) 2009-02-17 2015-09-24 ユーシービー ファーマ ソシエテ アノニム ヒトox40に対する特異性を有する抗体分子
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
CA2774692C (en) 2009-09-24 2017-12-19 Ucb Pharma S.A. Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes
TW201124427A (en) * 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
BR112012028557A2 (pt) 2010-05-07 2019-09-24 Xoma Tech Ltd uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
HUE033063T2 (hu) * 2010-05-14 2017-11-28 Abbvie Inc IL-1 kötõ fehérjék
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
PL2663577T3 (pl) 2011-01-14 2017-09-29 Ucb Biopharma Sprl Przeciwciało wiążące IL-17A i IL-17F
US9725516B2 (en) 2011-07-13 2017-08-08 Ucb Pharma, S.A. Bacterial host strain expressing recombinant DSBC
US9040048B2 (en) 2011-11-11 2015-05-26 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ5ac特異的ヒト化抗体およびその利用
WO2013157102A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ5ac特異的ヒト化抗体およびその利用
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Il-1結合蛋白質
CN104341501B (zh) * 2013-07-29 2019-08-30 上海睿智化学研究有限公司 抗IL-1β人源化单克隆抗体及其制备方法和应用
EP3096743A1 (en) 2014-01-20 2016-11-30 Eveon Process for reconstitution of a solid form of a pharmaceutical composition
US9560393B2 (en) * 2015-02-20 2017-01-31 Disney Enterprises, Inc. Media processing node
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB129105A (en) 1918-07-02 1919-07-02 Alfred George Hubble Improvements in and connected with Closing Means for Milk Churns, Containers and Vessels.
EP0569687B1 (en) 1984-05-18 2002-08-21 Massachusetts Institute Of Technology Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5474899A (en) * 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
AU703222B2 (en) 1995-01-23 1999-03-18 Xenotech Incorporated Composition to ameliorate osteolysis and metastasis
JPH09183799A (ja) * 1995-11-06 1997-07-15 Merck Patent Gmbh ヒト化モノクローナル抗体
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
AU2002355249A1 (en) * 2001-07-26 2003-02-17 Eli Lilly And Company Interleukin-1 beta antibodies
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products

Also Published As

Publication number Publication date
EP1597282B1 (en) 2011-09-21
CN1745103A (zh) 2006-03-08
BRPI0407233A (pt) 2006-01-31
CY1112507T1 (xx) 2015-12-09
CL2004000259A1 (es) 2005-04-15
SI1597282T1 (sl) 2012-02-29
JP4668896B2 (ja) 2011-04-13
IS8013A (is) 2005-09-07
GB0303337D0 (en) 2003-03-19
US20100158913A1 (en) 2010-06-24
MXPA05007392A (es) 2005-09-12
US8465744B2 (en) 2013-06-18
AR043159A1 (es) 2005-07-20
DK1597282T3 (da) 2012-01-23
TW200505942A (en) 2005-02-16
NO20054223L (no) 2005-11-08
ES2373953T3 (es) 2012-02-10
WO2004072116A2 (en) 2004-08-26
CA2515474A1 (en) 2004-08-26
AU2004210776A1 (en) 2004-08-26
KR20050099509A (ko) 2005-10-13
JP2007515925A (ja) 2007-06-21
EA200501286A1 (ru) 2006-02-24
US7608694B2 (en) 2009-10-27
JP2010246553A (ja) 2010-11-04
EP2287193A1 (en) 2011-02-23
PT1597282E (pt) 2012-01-05
US20060228358A1 (en) 2006-10-12
WO2004072116A3 (en) 2004-11-18
EP1597282A2 (en) 2005-11-23
AU2004210776B2 (en) 2011-04-07
NO20054223D0 (no) 2005-09-12
PL378412A1 (xx) 2006-04-03
PE20040947A1 (es) 2004-12-29
CA2515474C (en) 2013-11-12
AT525397T (de) 2011-10-15

Similar Documents

Publication Publication Date Title
ECSP088632A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina
AR060978A1 (es) Anticuerpos e inmunoconjugados y sus usos
NO20171697A1 (no) IL-17 Antagonistiske antistoffer
CY1112257T1 (xx) Μεθοδοι αγωγησ των φλεγμονωδων παθησεων χρησιμοποιωντασ ειδικουσ παραγοντεσ δεσμευσησ τησ ανθρωπινησ αγγειοποιητινησ-2
NO336186B1 (no) Kombinasjon av to Streptococcus pneumoniae proteiner, deres fremstilling og anvendelse i medisin som en vaksine.
CY1107628T1 (xx) Ανθρωπινα ctla-4 αντισωματα και χρησεισ αυτων
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
NO20055415L (no) Humaniserte antistoffer som gjenkjenner beta-amyloidpeptid
NO342964B1 (no) Blandinger som kan fremme sårheling
NI200700021A (es) Anticuerpos dirigidos contra péptido beta-amiloide y procedimientos que usan los mismos. pc19496a
MA29975B1 (fr) Antagonistes de la neuropiline
CR9995A (es) Anticuerpos monoclonales bifuncionales contra la placa beta amiloide
TR201821029T4 (tr) Geliştirilmiş antı-IL-23p19 antikorları.
CY1108436T1 (xx) Χορηγηση καψαϊκινοειδων
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
DE10192353T1 (de) Antikörpermolekül mit Spezifität für humanen Tumornekrosefaktor alpha und deren Verwendung
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
NO342491B1 (no) Humaniserte anti-beta7-antagonister og anvendelser av disse
RU2005101206A (ru) Упакованные вирусоподобные частицы, предназначенные для использования в качестве адъювантов, способы получения указанных частиц и их применение
UA116614C2 (uk) Антитіло до фактора d і його застосування
AR037109A1 (es) Uso de flibanserina
SA1463B1 (ar) مشتقات 2-oxo-1 ,وعملية لتحضيرها واستخداماتها
ITMO20030204A1 (it) Sacca per dialisi, set per dialisi comprendente detta
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
NO319063B1 (no) Medisinsk pasientsimulator